Welcome to LookChem.com Sign In|Join Free

CAS

  • or

109277-82-9

Post Buying Request

109277-82-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

109277-82-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 109277-82-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,9,2,7 and 7 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 109277-82:
(8*1)+(7*0)+(6*9)+(5*2)+(4*7)+(3*7)+(2*8)+(1*2)=139
139 % 10 = 9
So 109277-82-9 is a valid CAS Registry Number.

109277-82-9Relevant articles and documents

Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist

Scott, James S.,Moss, Thomas A.,Balazs, Amber,Barlaam, Bernard,Breed, Jason,Carbajo, Rodrigo J.,Chiarparin, Elisabetta,Davey, Paul R. J.,Delpuech, Oona,Fawell, Stephen,Fisher, David I.,Gagrica, Sladjana,Gangl, Eric T.,Grebe, Tyler,Greenwood, Ryan D.,Hande, Sudhir,Hatoum-Mokdad, Holia,Herlihy, Kara,Hughes, Samantha,Hunt, Thomas A.,Huynh, Hoan,Janbon, Sophie L. M.,Johnson, Tony,Kavanagh, Stefan,Klinowska, Teresa,Lawson, Mandy,Lister, Andrew S.,Marden, Stacey,McGinnity, Dermot F.,Morrow, Christopher J.,Nissink, J. Willem M.,O'Donovan, Daniel H.,Peng, Bo,Polanski, Radoslaw,Stead, Darren S.,Stokes, Stephen,Thakur, Kumar,Throner, Scott R.,Tucker, Michael J.,Varnes, Jeffrey,Wang, Haixia,Wilson, David M.,Wu, Dedong,Wu, Ye,Yang, Bin,Yang, Wenzhan

, p. 14530 - 14559 (2020)

Herein we report the optimization of a series of tricyclic indazoles as selective estrogen receptor degraders (SERD) and antagonists for the treatment of ER+breast cancer. Structure based design together with systematic investigation of each region of the molecular architecture led to the identification of N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine (28). This compound was demonstrated to be a highly potent SERD that showed a pharmacological profile comparable to fulvestrant in its ability to degrade ERα in both MCF-7 and CAMA-1 cell lines. A stringent control of lipophilicity ensured that 28 had favorable physicochemical and preclinical pharmacokinetic properties for oral administration. This, combined with demonstration of potent in vivo activity in mouse xenograft models, resulted in progression of this compound, also known as AZD9833, into clinical trials.

Ruthenium-Catalyzed Dehydrogenative N-Heterocyclization: Indoles from 2-Aminophenethyl Alcohols and 2-Nitrophenethyl Alcohols

Tsuji, Yasushi,Kotachi, Shinji,Huh, Keun-Tae,Watanabe, Yoshihisa

, p. 580 - 584 (2007/10/02)

Indole derivatives 3 were readily obtained from 2-aminophenethyl alcohols 1 in the presence of 2 mol percent (based on 1) of RuCl2(PPh3)3 under reflux in toluene.Indole (3a) was afforded from 2-aminophenethyl alcohol (1a) quantitatively.Other indoles (3) were also obtained in 73-99percent isolated yields from the corresponding 1, which were easily prepared by condensation between the corresponding 2-nitrotoluenes and aldehydes followed by reduction.During the reaction, a stoichiometric amount of hydrogen was spontaneously evolved into the gas phase.With a heterogeneous and homogeneous binary catalyst system, indoles were afforded in one pot from 2-nitrophenethyl alcohols 2 under a hydrogen atmosphere.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 109277-82-9